IBI3003

· Innovent Biologics (Suzhou) Co. Ltd.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for IBI3003, covering 2024-12-13 to 2026-02-25. Get the full timeline:

Most recent: Clinical Trial Update: A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]